RLYB News and Press, Rallybio Corporation

Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? PR Newswire Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shar...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 0.0% to $1.79 on volume of 996,349,655 shares Trio Petroleum Corp. (TPET) rose 166.7% to $1.12 on volume of 438,512,550 shares NVIDIA Corporation (NVDA) rose 3.0% to $182.48 on vol...

2026-03-02 16:17:48 ET Rallybio Corporation (RLYB) M&A Call March 2, 2026 8:30 AM EST Company Participants Steve Uden - Co-Founder, President, CEO & Director Kenneth Song - Chairman, President & CEO ... Read the full article on Seeking Alpha F...

Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders? PR Newswire Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareho...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 2.2% to $1.83 on volume of 883,419,339 shares Trio Petroleum Corp. (TPET) rose 157.5% to $1.0816 on volume of 411,497,833 shares Ondas Inc (ONDS) rose 2.6% to $10.34 on volume of 1...

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC, an ...

2026-03-02 09:49:41 ET More on Rallybio Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Read the full article on Seeking Alpha For further details see: Rallybio jumps on merg...

Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investor...

– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion Refractoriness Currently Planned for 2H 2026 with Potential for Topli...

2026-02-03 16:23:42 ET More on Rallybio Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Read the full article on Seeking Alpha For further details see: Rallybio to implement ...